Tevogen Bio Holdings Inc. (TVGN)
Nasdaq: TVGN · Biological Products, (No Diagnostic Substances) · Warren, NJ · filing with the SEC since 2021
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 31, 2026 | Apr 2, 2025 | Apr 29, 2024 | Apr 17, 2023 | Apr 1, 2022 |
| For lenders | |||||
| Net interest income | -195,618 | -184,037 | · | · | · |
| Research and development | 11,111,586 | 31,033,276 | 4,403,526 | · | · |
| General and administrative | 15,028,929 | 22,531,212 | 4,439,499r | 953,083 | · |
| Total operating expenses | 26,140,515 | 53,564,488 | 8,843,025 | · | · |
| Total costs and expenses | · | · | 2,273,970 | 953,083 | · |
| Operating income | -26,140,515 | -53,564,488 | -8,843,025 | · | · |
| Interest expense | · | 184,037 | 1,206,352r | · | · |
| Interest and investment income | · | · | 2,734,000 | 4,948,000 | · |
| Total non-operating income (expense) | · | · | 2,206,645 | 5,361,444 | · |
| Income tax expense | 4,750 | 1,750 | · | · | · |
| Net income including non-controlling interests | · | · | · | 4,408,361 | · |
| Net income | -26,275,432 | -13,727,380 | -60,477,680r | 4,408,361 | · |
| Net income to common shareholders | -26,825,432 | -10,273,695 | -60,477,680 | · | · |
| Earnings per share, basic | -8.08 | -3.50r | -122.00b | · | · |
| Earnings per share, diluted | -8.08 | -3.50r | -122.00b | · | · |
| Weighted average shares, basic | 3,319,812 | 2,933,451r | 495,040b | · | · |
| Weighted average shares, diluted | 3,319,812 | 2,933,451r | 495,040b | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-50 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding